118,957 Shares in VYNE Therapeutics Inc. $VYNE Acquired by Susquehanna International Group LLP

Susquehanna International Group LLP bought a new stake in shares of VYNE Therapeutics Inc. (NASDAQ:VYNE) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 118,957 shares of the company’s stock, valued at approximately $77,000. Susquehanna International Group LLP owned about 17.75% of VYNE Therapeutics at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Two Sigma Securities LLC bought a new position in shares of VYNE Therapeutics in the second quarter valued at $26,000. BlackRock Inc. acquired a new stake in shares of VYNE Therapeutics during the 2nd quarter valued at $29,000. XTX Topco Ltd bought a new stake in shares of VYNE Therapeutics during the 4th quarter worth $46,000. GSA Capital Partners LLP bought a new stake in shares of VYNE Therapeutics during the 2nd quarter worth $47,000. Finally, Rangeley Capital LLC grew its holdings in shares of VYNE Therapeutics by 18.1% in the 1st quarter. Rangeley Capital LLC now owns 118,064 shares of the company’s stock worth $71,000 after acquiring an additional 18,064 shares during the last quarter. 83.78% of the stock is currently owned by institutional investors.

VYNE Therapeutics Stock Down 0.8%

Shares of VYNE Therapeutics stock opened at $28.32 on Friday. VYNE Therapeutics Inc. has a 12-month low of $14.03 and a 12-month high of $79.75. The firm has a market capitalization of $18.98 million, a PE ratio of -74.54 and a beta of 2.00. The stock’s fifty day moving average is $31.40 and its 200-day moving average is $31.48.

VYNE Therapeutics (NASDAQ:VYNE) last released its quarterly earnings results on Thursday, August 13th. The company reported ($3.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($3.33). The company had revenue of $0.10 million during the quarter, compared to analyst estimates of $0.20 million. VYNE Therapeutics had a negative net margin of 4,726.21% and a negative return on equity of 70.42%.

VYNE Therapeutics Dividend Announcement

The company also recently announced a special dividend, which was paid on Thursday, July 23rd. Shareholders of record on Wednesday, July 22nd were issued a $19.00 dividend.

About VYNE Therapeutics

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.